In adult patients with IBD, at least 20% of flares are related to CDI, which worsens the clinical course of IBD, causes more frequent hospitalizations, and increases the risk of colectomy. 7, 8 CDI also worsens the course of IBD in children; however, data are limited. 9, 10 The observation that CDI worsens the IBD course is reflected in the European Crohn's and Colitis Organization (ECCO) recommendations on the management of CDI in IBD. 11 According to these recommendations, in the case of exacerbation of the symptoms of IBD and a diagnosis of CDI, it is recommended to treat with a targeted therapy. There are no controlled clinical trials (randomized or nonrandomized) on the treatment of CDI either in adults or in children with IBD. In addition, observational studies are limited. 10, [12] [13] [14] [15] [16] [17] Therefore, management algorithms for this group of patients are extrapolated from the non-IBD patients. Moreover, there are no prospective trials for CDI therapy in otherwise healthy children. Thus, recommendations or statements on the treatment of CDI in children duplicate those intended for adults. That is, the recommendations for CDI treatment in children with IBD are identical to the recommendations for the healthy adult population. 18, 19 The drugs mostly used include the following: metronidazole, vancomycin, rifaximin, and, more recently, fidaxomicin. In summary, in the case of mild or moderate infections, metronidazole is the drug of choice at a dose of 500 mg 3 times a day for adults and 7.5 mg/kg 3 times a day for children for 10 to 14 days. However, it seems that the effectiveness of metronidazole in treating CDI has decreased; it was determined as inefficient in 22% of cases in 2003 to 2004 20 compared with 2% in 1982 to 1991. 21 Vancomycin is a drug reserved for a severe course of the disease and for the treatment of CDI relapse. In the 2 retrospective small studies on patients with IBD, treatment with metronidazole, compared with vancomycin, was associated with poor outcomes (higher colectomy rates, longer hospital stays, and more frequent readmission) in adults but not in children. 12, 22 Fidaxomicin has only been assessed in a small (n ¼ 21) open-label study and was shown to be effective (resolution or improvement of diarrhea) in all patients with IBD. 17 Rifaximin, a rifamycin-based antibiotic, is a promising drug for the treatment of recurrent CDI. 23 It has minimal absorption from the intestinal system, creates a very limited adverse drug reaction, and generates only very little, short-term antibiotic resistance. 24 It also demonstrated significant activity in vitro against C. difficile. 25, 26 In the only study (n ¼ 10) assessing the treatment of recurrent CDI in patients with IBD, treatment with rifaximin in tapering doses (200 mg 3 times daily for 14 d, 200 mg once daily for 14 d, and 200 mg every other day for the final 14 d) prevented a recurrence in all patients. 27 Recently, in addition to drug therapy, fecal microbiota transplantation (FMT) seems to be a very promising option for the treatment of recurrent CDI and has an effectiveness between 79% and 86%. 28, 29 Initially, we planned to compare the effectiveness of the 2 most commonly used antibiotics for treatment of CDI: metronidazole and vancomycin. However, vancomycin is available only for hospital distribution in Poland. Because we planned the study among outpatients with IBD, we had to choose other antibiotics than vancomycin; thus, we chose rifaximin that is very safe and has been previously established for the treatment of CDI. 30 Because there are no prospective trials on the treatment of CDI in patients with IBD, we planned a study comparing metronidazole and rifaximin in the treatment of CDI in pediatric patients with IBD.
MATERIALS AND METHODS
This was a prospective, single-blind randomized study. The study was conducted between October 2012 and December 2014 at the Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Poland. Inclusion criteria were as follows: age between 12 and 18 years, IBD diagnosed according to the revised Porto criteria, 31 CDI diagnosed by a positive enzyme immunoassay (EIA) stool test for C. difficile toxins A and/or B (C. difficile TOX A/B II TM; TechLab, Inc., Blacksburg, VA), mild or moderate symptoms of CDI, and consent from parents. We excluded children who underwent any antibiotic treatment up to 2 weeks before entering the study.
The severity of Crohn's disease (CD) and ulcerative colitis (UC) was evaluated using the Pediatric Crohn's Disease Activity Index (PCDAI) and the Pediatric Ulcerative Colitis Activity Index (PUCAI), which include symptoms, physical examination findings and laboratory test results; a PCDAI score #10 for CD and a PUCAI score ,10 for UC were defined as remission.
We used the following CDI activity assessment: mild, a lack of increase of leukocytes in the blood and ,3 loose stools within 24 hours; moderate, leukocytosis ,15,000 and 3 to 5 loose stools within 24 hours; and severe, leukocytosis .15,000, creatinine level .50% above the norm, temperature .38.58C, and heavy colitis (clinical and radiological symptoms). 32 Recurrence was defined as a repeat CDI within 2 to 8 weeks. 33 The primary endpoint was a cure rate defined as the percentage of patients with a negative EIA stool test for C. difficile toxins A and B measured at 4 weeks after the end of treatment. We also assessed if the immunosuppressed drugs influenced the cure rates and if there was a difference in IBD activity before and after the treatment.
Children with IBD and CDI, who met the inclusion criteria after physical examination, were asked about symptoms such as fever, diarrhea, bloody diarrhea, abdominal pain, and the current IBD treatment. IBD activity was evaluated on the PCDAI scale for patients with CD and on the PUCAI scale for patients with UC. Then, patients randomly, based on a computer-generated randomization list with blocks of size 4, received one of 2 drugs: metronidazole or rifaximin, orally, every 8 hours for 14 days. The dosage depended on the patient's body weight and is presented below.
On the randomization list, each number was allocated to the letter "A" or "B." At enrollment, a nurse who was not involved in the study assigned consecutive randomization numbers to participants. Study drugs were prepared in white paper envelopes signed A or B. The IBD nurse who was not related to the study was given the consecutive patients' product A or B. Researchers, outcome assessors, and a person responsible for the statistical analysis were masked to the intervention until the completion of the study. The information on intervention assignments was stored in a sealed envelope in a lockable cabinet in the administrative part of the department.
At 4 weeks after the end of the study, PCDAI and PUCAI assessments were performed, and the EIA stool test for C. difficile toxins A and B was performed again.
Initially, the study was powered to detect a difference of 20% between groups. 
RESULTS
All patients who were asked to participate completed the study according to the protocol. In total, we included 31 patients with IBD, 12 with CD and 19 with UC. There were no significant differences between CD and UC patients regarding median age (14.5 versus 15 years, respectively, P ¼ 0.8), median disease activity (10 [7.5-30] points versus 10 [5-25] points, respectively, P ¼ 0.6), and immunosuppressive treatment (75% versus 63.2%, respectively, P ¼ 0.6).
Of the 31 patients enrolled, 17 were randomized into the metronidazole group and 14 were randomized into the rifaximin group. We found no statistically significant differences between the 2 study groups, including age, type of treatment, and disease activity, and the results are demonstrated in Table 1 . Most patients (21/31) were on immunosuppressive therapy including 7 patients who were receiving combination (immunomodulatory plus biological) therapy.
There was no statistically significant difference in the cure rate (the primary endpoint) between patients treated with metronidazole and rifaximin (70.6% versus 78.6%, respectively, P ¼ 0.5). We found no difference in the recurrence rate between the 2 study treatment types (17% versus 0%, respectively, P ¼ 0.3). The detailed data on the effectiveness of CDI treatment are presented in Table 2 . We also did not find an association between the immunosuppressive therapies and cure rate or recurrence rate (Table 3) .
DISCUSSION
In this prospective comparable trial, we found that cure rates in patients with IBD treated with metronidazole were similar to those treated with rifaximin (P ¼ 0.5). This is the first nonobservational trial assessing the effectiveness of CDI treatment in this group of patients among both adults and children. We were unable to compare our results with the results of intervention studies on patients with IBD; therefore, we compared them with the results of observational studies on patients with IBD and with the results of intervention studies on an otherwise healthy population.
To date, there are only a few observational studies assessing the treatment of CDI in patients with IBD. Mezoff et al, 10 in their retrospective study, identified 29 patients #18 years old with IBD and CDI from a hospital IBD database. The initial treatment included metronidazole, vancomycin, and nitazoxanide. The overall cure rate for the initial treatment was 43% (no detailed data given) and was irrespective of the type of IBD. Final treatment, after up to 5 treatment changes, was successful in 41% (15/37) for metronidazole and 43% (16/37) for vancomycin in that study. The prospective study was performed by Gryboski. 12 The author described 10 patients with flare of IBD and CDI who were treated with metronidazole (6/10), vancomycin (3/10), or both drugs (1/10). A clinical cure was noted in all patients and was accompanied by the elimination of the toxin from stools. 12 In the only systematic review of CDI in IBD by Goodhand et al, 15 which included all original, cross-sectional cohort and case-control studies published up to September 2010, only a few studies reported treatment. In those studies, 88% (300/340) of patients were treated with metronidazole, vancomycin, or both, and in most cases (88%, 258/292 patients), this treatment was successful. More recently, 2 other retrospective studies assessing treatment of CDI in patients with IBD were published. 14, 16 The Fadi et al study assessed all patients with IBD and CDI who were admitted to the hospital. Of them, 22 were treated with metronidazole, 11 were treated with vancomycin, and 10 received both. A clinical cure was observed in 55% of patients receiving metronidazole and in 100% of patients receiving vancomycin, P ¼ 0.01. 14 Bownik et al found no difference in the cure rate between metronidazole-treated patients and those treated with vancomycin (80% versus 78%, P ¼ 0.86). In that study, all patients were treated as outpatients for their first episode of CDI. 16 In the retrospective study, Spiceland et al 17 reported that 21 patients with IBD and CDI were treated with fidaxomicin. All those patients had resolution of diarrhea or improvement in diarrhea and a negative C. difficile test. FMT was found to be effective (resolution of CDI in 86% of patients after a single FMT) when treating CDI in patients with IBD. 29 A recently published review by the Cochrane Collaboration included randomized controlled trials assessing antibiotic treatment for CDI, and vancomycin was found to be more effective than metronidazole for achieving a symptomatic cure defined as initial symptomatic response and no recurrence of CDI: 79% versus 72%, respectively (relative risk [RR] 0.90, 95% confidence interval, 0.84-0.97). Moreover, fidaxomicin and teicoplanin were found to be more effective than vancomycin for achieving a symptomatic cure: 71% versus 61%, respectively (RR 1.17, 95% confidence interval, 1.04-1.31) and 87% versus 73%, respectively (RR 1.21, 95% confidence interval, 1.00-1.46). 37 It is impossible to combine the results from these few studies because of their heterogeneity regarding population and the different outcomes and laboratory methods used for the diagnosis of CDI. The effectiveness of treatment with metronidazole (and rifaximin as there is no difference between the 2 treatments in this study) that we found is similar to that reported by all studies assessing the treatment of mild-to-moderate CDI both in patients with IBD and healthy populations. However, observations that metronidazole use is associated with a higher rate of colectomy and longer length of hospital stay 38 comes from studies on IBD patients with severe CDI, which strongly suggests limited use of metronidazole for treating patients with IBD who experience mild-to-moderate CDI and a mild flare of IBD.
We did not find any correlation between the cure rate and immunosuppressive treatment of IBD. This result is in line with several previous studies conducted by Bowik et al, Fadi et al, 14, 16 and Ananthakrishnan et al, but it opposes others. 39 Ben-Horin et al also did not find any difference in the cure rate between patients who were treated with metronidazole and were or were not on immunomodulators (93% versus 84%, P ¼ 0.09); however, multivariant analysis showed that receiving an antibiotic (mostly metronidazole) and immunomodulator was associated with a higher frequency of mortality or colectomy, colon perforation or megacolon, and shock or the need for mechanical ventilation (all these components taken together were defined as the primary outcome). All patients were hospitalized in that study. 39 A recently published American Gastroenterology Association's expert review suggests that antibiotic therapy alone in the case of CDI in patients with acute severe IBD should not be recommended. Moreover, in these cases, along with antibiotics, maintenance of immunomodulatory therapy, starting glucocorticosteroids, or even escalation of immunosuppressive therapy is recommended. 40 We suggest that nonwithdrawal of immunosuppressive treatment in mild-to-moderate IBD is also preferable. We planned a short, within 8 weeks, follow-up assessment to evaluate the recurrence rate. The recurrence of CDI was found in a small subset of patients and was irrespective of study treatment type (P ¼ 0.3). The recurrence rate after initial treatment with metronidazole, we observed, was lower than that previously reported in both children (34%) 13 and adults (31%-32%). 14, 16 Several factors hamper these result comparisons. All these studies were retrospective, and 2 of them were published only as abstracts. 14, 16 Moreover, in the study by Kelsen et al, 13 only hospitalized patients with their first episode of CDI were assessed when approximately half of our patients had a history of CDI and all were outpatients. Moreover, in the study by Kelly et al, 29 44% of patients were new-onset of IBD compared with 0% in our study. Finally, Bownik et al 16 considered episodes of CDI within 12 months as recurrence compared with the more common 2 months.
We also noted no association between the recurrence rate and immunosuppressive treatment (P ¼ 0.6). Our results are in line with those of all studies that assessed CDI recurrences in patients with IBD. The data are limited; however, it seems that immunosuppressive treatment does not influence CDI treatment outcomes.
The biggest advantage of our study is the fact that this is the first study assessing the effectiveness of treatment of CDI in patients with IBD in a prospective, controlled manner. Our study also has several limitations. The study was single-center, single-blinded, and limited to outpatients. The main shortcoming of the study is the fact that it has been stopped early; therefore, it is not powered enough. The study groups were small but large enough to perform statistical analysis. Considering our trial as a pilot study, we estimated the sample size for future studies. Based on the assumption that alpha ¼ 0.05 and beta ¼ 0.2, the total sample size is 942 (471 in each group). Our study has also minor limitations. We did not perform microbiological assessment of C. difficile strains, i.e., polymerase chain reaction ribotyping, so we were not able to distinguish CDI relapse (infection caused by the same strain) and CDI reinfection (infection by a new strain); however, no published studies have used such methods. Moreover, we did not perform endoscopic evaluation that is a part of IBD activity assessment; however, its usefulness for CDI diagnosis is limited.
There are 2 clinical implications of our findings. First, there is one more treatment option for children with IBD and mild CDI, who do not tolerate metronidazole. It also may be important for these children who are on metronidazole for long time from other than CDI reasons, i.e., perianal fistulas. In addition, in Poland, as in many countries in Europe, microbial resistance to metronidazole for many bacterial species (i.e., Helicobacter pylori) is high, so we may expect that we have to look for other treatment possibilities. 41 The other important issue regarding the study is the fact that we have already convinced how difficult is to plan and conduct a prospective, randomized trial assessing effectiveness of CDI treatment in patients with IBD. We realize why there is so huge paucity of such studies worldwide. Because of a similarity of symptoms of CDI and an IBD flare, it is impossible to establish if the improvement is a result of CDI cure or an overall effect of antibiotic therapy on inflammation. Despite many limitations of our study, we believe that our findings may help to plan a prospective multicenter study to evaluate the effectiveness of CDI therapy in patients with IBD. In addition, for those patients with mild-to-moderate activity of IBD and mild CDI, it may be reasonable to plan a randomized study. One arm would include escalation of IBD treatment; the second arm would include escalation of IBD treatment plus metronidazole therapy. Close observation of clinical symptoms, number of stools, calprotectin level etc. day by day minimum for 7 days may be helpful to establish the real impact of CDI on severity of IBD.
CONCLUSIONS
In this prospective controlled trial, we found that metronidazole and rifaximin have similar effectiveness in the treatment of CDI in pediatric patients with IBD.
